financetom
Business
financetom
/
Business
/
Insmed's blood pressure drug meets main goal in mid-stage trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insmed's blood pressure drug meets main goal in mid-stage trial
Jun 10, 2025 4:22 AM

June 10 (Reuters) - Insmed ( INSM ) said on Tuesday that

its experimental blood pressure drug met the main goals in a

mid-stage study.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Innovative Industrial Properties Q1 Adjusted Funds From Operations, Revenue Decline
Innovative Industrial Properties Q1 Adjusted Funds From Operations, Revenue Decline
May 9, 2024
05:32 AM EDT, 05/09/2024 (MT Newswires) -- Innovative Industrial Properties ( IIPR ) reported late Wednesday Q1 adjusted funds from operations of $2.21 per share, down from $2.25 a year earlier. Revenue for the quarter ended March 31 was $75.5 million, down from $76.1 million a year earlier. Analysts polled by Capital IQ expected $78.5 million. Price: 105.01, Change: -2.69,...
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
May 9, 2024
May 9 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Thursday: ** SoftBank CEO Junichi Miyakawa said that the Japanese telecommunications firm is in talks with South Korea's Naver over control of LY Corp ( YAHOF ), which operates the popular messaging app Line. ** Spanish bank BBVA presented a 12.23 billion euro...
Azenta Swings to Fiscal Q2 Adjusted Profit, Revenue Increases; 2024 Guidance Updated; Chief Executive Schwartz to Retire
Azenta Swings to Fiscal Q2 Adjusted Profit, Revenue Increases; 2024 Guidance Updated; Chief Executive Schwartz to Retire
May 9, 2024
05:40 AM EDT, 05/09/2024 (MT Newswires) -- Azenta ( AZTA ) reported fiscal Q2 adjusted earnings Wednesday of $0.05 per diluted share, swinging from an adjusted loss of $0.06 a year earlier. Analysts polled by Capital IQ expected normalized earnings of $0.02. Total revenue for the quarter ended March 31 was $159.1 million, up from $148.4 million a year earlier....
Topgolf Callaway Brands' Q1 Non-GAAP Earnings, Revenue Decline
Topgolf Callaway Brands' Q1 Non-GAAP Earnings, Revenue Decline
May 9, 2024
05:41 AM EDT, 05/09/2024 (MT Newswires) -- Topgolf Callaway Brands ( MODG ) reported Q1 non-GAAP earnings late Wednesday of $0.09 per diluted share, down from $0.17 a year earlier. Analysts polled by Capital IQ expected $0.01. Revenue for the quarter ended March 31 was $1.14 billion, compared with $1.17 billion a year earlier. Analysts polled by Capital IQ expected...
Copyright 2023-2026 - www.financetom.com All Rights Reserved